{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:02:40Z","timestamp":1789682560067,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI17\/00251"],"award-info":[{"award-number":["PI17\/00251"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40121-021-00570-z","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T14:02:50Z","timestamp":1638540170000},"page":"335-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort Study"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-068X","authenticated-orcid":false,"given":"Inmaculada","family":"L\u00f3pez Montesinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"G\u00f3mez-Zorrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaira Raquel","family":"Palacios-Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Prim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Echeverria-Esnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Milagro","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Dur\u00e1n-Jord\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Sorli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Guerri-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Horcajada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PROA PSMAR group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"570_CR1","doi-asserted-by":"crossref","unstructured":"Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32:e00031\u201319. http:\/\/cmr.asm.org\/content\/32\/4\/e00031-19.abstract.","DOI":"10.1128\/CMR.00031-19"},{"key":"570_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","volume":"21\u201322","author":"A Oliver","year":"2015","unstructured":"Oliver A, Mulet X, L\u00f3pez-Causap\u00e9 C, Juan C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat. 2015;21\u201322:41\u201359. https:\/\/doi.org\/10.1016\/j.drup.2015.08.002.","journal-title":"Drug Resist Updat"},{"key":"570_CR3","doi-asserted-by":"publisher","first-page":"e0178178","DOI":"10.1371\/journal.pone.0178178","volume":"12","author":"JL Lamas Ferreiro","year":"2017","unstructured":"Lamas Ferreiro JL, \u00c1lvarez Otero J, Gonz\u00e1lez Gonz\u00e1lez L, et al. Pseudomonas aeruginosa urinary tract infections in hospitalized patients: mortality and prognostic factors. PLoS ONE. 2017;12:e0178178. https:\/\/doi.org\/10.1371\/journal.pone.0178178.","journal-title":"PLoS ONE"},{"key":"570_CR4","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/jac\/dkz147","volume":"74","author":"E del Barrio-Tofi\u00f1o","year":"2019","unstructured":"del Barrio-Tofi\u00f1o E, Zamorano L, Cortes-Lara S, et al. Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. J Antimicrob Chemother. 2019;74:1825\u201335. https:\/\/doi.org\/10.1093\/jac\/dkz147.","journal-title":"J Antimicrob Chemother"},{"key":"570_CR5","doi-asserted-by":"crossref","unstructured":"Goodlet KJ, Benhalima FZ, Nailor MD. A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy? Antimicrob Agents Chemother. 2018;63. https:\/\/aac.asm.org\/content\/63\/1\/e02165-18.","DOI":"10.1128\/AAC.02165-18"},{"key":"570_CR6","doi-asserted-by":"crossref","unstructured":"Vogel-Gonz\u00e1lez M, Tall\u00f3-Parra M, Herrera-Fern\u00e1ndez V, et al. Low zinc levels at admission associates with poor clinical outcomes in SARS-CoV-2 infection. Nutrients. 2021;13:562. https:\/\/www.mdpi.com\/2072-6643\/13\/2\/562.","DOI":"10.3390\/nu13020562"},{"key":"570_CR7","doi-asserted-by":"publisher","unstructured":"Luque S, Esca\u00f1o C, Sorli L, et al. Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrug-resistant gram-negative bacterial infections. Antimicrob Agents Chemother. 2017;61. https:\/\/doi.org\/10.1128\/AAC.02595-16.","DOI":"10.1128\/AAC.02595-16"},{"key":"570_CR8","doi-asserted-by":"crossref","unstructured":"Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724\u20131728. https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/s.","DOI":"10.1086\/599225"},{"key":"570_CR9","doi-asserted-by":"publisher","unstructured":"Destache CJ. Aminoglycoside-induced nephrotoxicity\u2014a focus on monitoring. J Pharm Pract 2014; 27:562\u2013566. https:\/\/doi.org\/10.1177\/0897190014546102.","DOI":"10.1177\/0897190014546102"},{"key":"570_CR10","doi-asserted-by":"crossref","unstructured":"Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589\u2013601. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309906705801.","DOI":"10.1016\/S1473-3099(06)70580-1"},{"key":"570_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/jac\/dkm193","volume":"60","author":"L Vidal","year":"2007","unstructured":"Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60:247\u201357.","journal-title":"J Antimicrob Chemother"},{"key":"570_CR12","doi-asserted-by":"publisher","unstructured":"Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008;61:636\u2013642. https:\/\/doi.org\/10.1093\/jac\/dkm511.","DOI":"10.1093\/jac\/dkm511"},{"key":"570_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/mdr.2010.0170","volume":"17","author":"E-J Joo","year":"2011","unstructured":"Joo E-J, Kang C-I, Ha YE, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist. 2011;17:305\u201312.","journal-title":"Microb Drug Resist"},{"key":"570_CR14","doi-asserted-by":"crossref","unstructured":"Britt NS, Ritchie DJ, Kollef MH, et al. Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant Pseudomonas aeruginosa sepsis. Antimicrob Agents Chemother. 2018;62. https:\/\/aac.asm.org\/content\/62\/4\/e02400-17.","DOI":"10.1128\/AAC.02400-17"},{"key":"570_CR15","doi-asserted-by":"publisher","unstructured":"Karam G, Chastre J, Wilcox MH, Vincent J-L. Antibiotic strategies in the era of multidrug resistance. Crit Care. 2016;20:136. https:\/\/doi.org\/10.1186\/s13054-016-1320-7.","DOI":"10.1186\/s13054-016-1320-7"},{"key":"570_CR16","doi-asserted-by":"crossref","unstructured":"Kazakova S V, Baggs J, McDonald LC, et al. Association between antibiotic use and hospital-onset clostridioides difficile infection in US Acute Care Hospitals, 2006\u20132012: an ecologic analysis. Clin Infect Dis. 2020;70:11\u201318. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30820545.","DOI":"10.1093\/cid\/ciz169"},{"key":"570_CR17","doi-asserted-by":"crossref","unstructured":"Huang W, Qiao F, Zhang Y, et al. In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae. Clin Infect Dis. 2018;67:S225\u2013S230. https:\/\/academic.oup.com\/cid\/article\/67\/suppl_2\/S225\/5181281.","DOI":"10.1093\/cid\/ciy642"},{"key":"570_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"570_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"570_CR20","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/CCM.0b013e31819def97","volume":"37","author":"AE Jones","year":"2010","unstructured":"Jones AE, Trzeciak SKJ. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2010;37:1649\u201354.","journal-title":"Crit Care Med"},{"key":"570_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour C, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). J Am Med Assoc. 2016;315:801\u201310.","journal-title":"J Am Med Assoc"},{"key":"570_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/SHK.0b013e318182f98f","volume":"31","author":"JY Rhee","year":"2009","unstructured":"Rhee JY, Kwon KT, Ki HK, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the PITT bacteremia score and the acute physiology and chronic health evaluation II scoring systems. Shock. 2009;31:146\u201350.","journal-title":"Shock"},{"key":"570_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","volume":"137","author":"ND Friedman","year":"2002","unstructured":"Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791\u20137.","journal-title":"Ann Intern Med"},{"key":"570_CR24","doi-asserted-by":"crossref","unstructured":"Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008;73:538\u2013546. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815530445.","DOI":"10.1038\/sj.ki.5002743"},{"key":"570_CR25","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone. https:\/\/www.eucast.org\/ast_of_bacteria\/previous_versions_of_documents\/. Accessed 15 Oct 2021."},{"key":"570_CR26","doi-asserted-by":"crossref","unstructured":"Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71:304\u2013310. https:\/\/academic.oup.com\/cid\/article\/71\/2\/304\/5572677.","DOI":"10.1093\/cid\/ciz816"},{"key":"570_CR27","doi-asserted-by":"publisher","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150\u2013161. https:\/\/doi.org\/10.1002\/pst.433.","DOI":"10.1002\/pst.433"},{"key":"570_CR28","doi-asserted-by":"crossref","unstructured":"Karaiskos I, Antoniadou A, Giamarellou H. Combination therapy for extensively-drug resistant gram-negative bacteria. Expert Rev Anti Infect Ther. 2017;15:1123\u20131140. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29172792.","DOI":"10.1080\/14787210.2017.1410434"},{"key":"570_CR29","doi-asserted-by":"publisher","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDS. Pharmacother J Hum Pharmacol Drug Ther. 2019;39:10\u201339. https:\/\/doi.org\/10.1002\/phar.2209.","DOI":"10.1002\/phar.2209"},{"key":"570_CR30","unstructured":"WHO. Antimicrobial stewardship programmes in low- and middle-income countries. A practical toolkit. Geneva: World Health Organization; Licence CC BY-NC-SA 30."},{"key":"570_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/cid\/cix182","volume":"65","author":"G Haidar","year":"2017","unstructured":"Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65:110\u201320.","journal-title":"Clin Infect Dis"},{"key":"570_CR32","doi-asserted-by":"crossref","unstructured":"Sanz-Garc\u00eda F, Hernando-Amado S, Mart\u00ednez JL. Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime-avibactam. Antimicrob Agents Chemother. 2018;62. https:\/\/aac.asm.org\/content\/62\/10\/e01379-18.","DOI":"10.1128\/AAC.01379-18"},{"key":"570_CR33","doi-asserted-by":"crossref","unstructured":"Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019;53:408\u2013415. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303261.","DOI":"10.1016\/j.ijantimicag.2018.11.001"},{"key":"570_CR34","doi-asserted-by":"publisher","unstructured":"Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;5. https:\/\/doi.org\/10.1093\/ofid\/ofy280\/5149696.","DOI":"10.1093\/ofid\/ofy280\/5149696"},{"key":"570_CR35","doi-asserted-by":"crossref","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections. Antimicrob Agents Chemother. 2020;64. https:\/\/aac.asm.org\/content\/64\/4\/e02291-19.","DOI":"10.1128\/AAC.02291-19"},{"key":"570_CR36","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391\u2013400. https:\/\/doi.org\/10.1016\/S1473-3099(18)30099-9.","journal-title":"Lancet Infect Dis"},{"key":"570_CR37","doi-asserted-by":"crossref","unstructured":"Sorl\u00ed L, Luque S, Li J, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical. J Infect. 2019;79:253\u2013261. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445319301926.","DOI":"10.1016\/j.jinf.2019.06.011"},{"key":"570_CR38","doi-asserted-by":"crossref","unstructured":"Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55:5893\u20135899. https:\/\/aac.asm.org\/content\/55\/12\/5893.","DOI":"10.1128\/AAC.00387-11"},{"key":"570_CR39","doi-asserted-by":"publisher","unstructured":"Zavascki AP, Klee BO, Bulitta JB. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther. 2017;15:519\u2013526. https:\/\/doi.org\/10.1080\/14787210.2017.1316193.","DOI":"10.1080\/14787210.2017.1316193"},{"key":"570_CR40","doi-asserted-by":"publisher","unstructured":"van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dku495.","DOI":"10.1093\/jac\/dku495"},{"key":"570_CR41","doi-asserted-by":"publisher","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available: Table\u00a01. Am J Epidemiol. 2016;183:758\u2013764. https:\/\/doi.org\/10.1093\/aje\/kwv254.","DOI":"10.1093\/aje\/kwv254"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00570-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00570-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00570-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:42:35Z","timestamp":1644946955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00570-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00570-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"assertion":[{"value":"16 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}